Capital Advisors Ltd’s Haemonetics HAE Stock Holding History

Capital Advisors Ltd’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4	Closed	–	–	1466
2025 Q4	$0	Buy	+4	New	+$269	﹤0.01%	1442

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Advisors Ltd's HAE Position: Q1 2026 in Review

Capital Advisors Ltd sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 4 shares.

Capital Advisors Ltd first reported a position in HAE in Q4 2025 and held it in 1 quarter. The position peaked at $0 in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

Capital Advisors Ltd reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
Capital Advisors Ltd sold 4 Haemonetics shares in Q1 2026.
Capital Advisors Ltd first reported a position in Haemonetics in Q4 2025 and held it in 1 quarter.
Capital Advisors Ltd's Haemonetics position peaked at $0 in Q4 2025.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Capital Advisors Ltd's 13F filing for Q1 2026, filed 16 Apr 2026.